Serum ROCK2, miR-300 and miR-450b-5p levels in two different clinical phenotypes of multiple sclerosis: Relation to patient disability and disease progression,Journal of Neuroimmunology

当前位置： X-MOL 学术 › J. Neuroimmunol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Serum ROCK2, miR-300 and miR-450b-5p levels in two different clinical phenotypes of multiple sclerosis: Relation to patient disability and disease progression
Journal of Neuroimmunology ( IF 2.9 ) Pub Date : 2020-10-01 , DOI: 10.1016/j.jneuroim.2020.577356
Samar H Ibrahim ₁ , Karim M El-Mehdawy ₂ , Mae Seleem ₁ , Maha M El-Sawalhi ₃ , Amira A Shaheen ₃

Affiliation

Relapsing remitting multiple sclerosis (RRMS) is the most prevalent MS subtype. Years after disease onset, most of RRMS patients show transition into secondary progressive form (SPMS). Currently, no biomarkers are available for tracking disease progression. Here, we observed marked elevation of Rho-associated protein kinase 2 (ROCK2) along with significant downregulation of miRNAs 300 and 450b-5p expressions in the serum of 39 RRMS and 35 SPMS Egyptian patients compared to healthy controls. More pronounced alterations were found in SPMS versus RRMS patients. Our findings also suggest relations between elevated ROCK2 and reduced expression of both miRNAs with the degree of disability and disease progression. Notably, these biomarkers effectively discriminated RRMS from SPMS patients with miR-450b-5p showing the highest prognostic power.

中文翻译：

多发性硬化症两种不同临床表型中的血清 ROCK2、miR-300 和 miR-450b-5p 水平：与患者残疾和疾病进展的关系

复发缓解型多发性硬化症 (RRMS) 是最普遍的 MS 亚型。疾病发作多年后，大多数 RRMS 患者表现出过渡到继发性进行性形式 (SPMS)。目前，没有可用于跟踪疾病进展的生物标志物。在这里，我们观察到与健康对照相比，39 名 RRMS 和 35 名 SPMS 埃及患者的血清中 Rho 相关蛋白激酶 2 (ROCK2) 的显着升高以及 miRNA 300 和 450b-5p 表达的显着下调。在 SPMS 与 RRMS 患者中发现了更明显的改变。我们的研究结果还表明 ROCK2 升高和两种 miRNA 表达降低与残疾程度和疾病进展之间的关系。值得注意的是，这些生物标志物有效地将 RRMS 与具有最高预后能力的 miR-450b-5p 的 SPMS 患者区分开来。

更新日期：2020-10-01

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南11